header logo image


Page 1,492«..1020..1,4911,4921,4931,494..1,5001,510..»

Clinical Trial for Myelofibrosis that Targets Cancer Stem Cells | CIRM Spotlight on Genomics – Video

February 1st, 2012 1:31 pm

24-01-2012 18:39 Four minute excerpt from the Spotlight on Genomics seminar presentation during the January 17th 2012 California Institute for Regnerative Medicine governing board meeting. The video features a conversation between Catriona Jamieson, director for stem cell research at UCSD Moores Cancer Center, and one of her patients who is participating in a clinical trial for the treatment of myelofibrosis, a life-threatening blood disorder.

View original post here:
Clinical Trial for Myelofibrosis that Targets Cancer Stem Cells | CIRM Spotlight on Genomics - Video

Read More...

An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use – James P. Watson, MD – Video

February 1st, 2012 1:31 pm

31-01-2012 13:32 James P. Watson, MD lecture sample from the 11th Clinical Applications for Age Management Medicine Conference, Fall 2011, Las Vegas, Nevada Pre-Conference Track 2: Regenerative and Cell Based Medicine This lecture focused on regenerative and cell-based medicine, Autologous Stem Cell Research. This field continues to grow in use by physicians across the world. From platelet rich plasma to culture expanded stem cells, the need for information about the applications of these therapies to treat patients has never been greater. This track will focus on the latest developments in cell-based medicine with speakers who are driving the research and using these technologies as part of their everyday practice of medicine. For more information about our upcoming conference visit our website http://www.agemed.org Or contact us at conference@agemed.org

Continued here:
An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video

Read More...

Cell Therapy – Technologies, Markets and Companies

February 1st, 2012 1:31 pm

NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cell Therapy - Technologies, Markets and Companies

http://www.reportlinker.com/p0203537/Cell-Therapy---Technologies-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2011, and projected to 2021.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 278 of these are profiled in part II of the report along with tabulation of 268 alliances. Of these companies, 160 are involved in stem cells. Profiles of 69 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 52 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

CELL THERAPY -1TABLE OF CONTENTS0. Executive Summary 231. Introduction to Cell Therapy 27Introduction 27Historical landmarks of cell therapy 27Interrelationship of cell therapy technologies 29Cells and organ transplantation 29Cells and protein/gene therapy 30Cell therapy and regenerative medicine 31Cells therapy and tissue engineering 31Therapy based on cells involved in disease 32Advantages of therapeutic use of cells 32Cell-based drug delivery 33Cells as vehicles for gene delivery 33Red blood cells as vehicles for drug delivery 33Advantages of cell-based drug delivery 34Limitations of cell-based drug delivery 342. Cell Therapy Technologies 35Introduction 35Cell types used for therapy 35Sources of cells 35Xenografts 36Cell lines 36Immortalized cells 36Blood component therapy 36Therapeutic apheresis 36Leukoreduction 37Platelet therapy 37Basic technologies for cell therapy 38Cell culture 38Automated cell culture devices 38Cell culture for adoptive cell therapy 39Observation of stem cell growth and viability 39Companies involved in cell culture 39Cell sorting 41Flow cytometry 41A dielectrophoretic system for cell separation 42Adult stem cell sorting by identification of surface markers 42ALDESORTER system for isolation of stem cells 42Dynabead technology for cell sorting 42Molecular beacons for specific detection and isolation of stem cells 43Multitarget magnetic activated cell sorter 43Nanocytometry 43Scepter™ cytometer 44Companies supplying cell sorters 44Cell analysis 45Cell analyzers 45In vivo cell imaging 45Measuring cell density 46Single-cell gene expression analysis 46Preservation of cells 47Innovations in cryopreservation 47Packaging of cells 48Selective expansion of T cells for immunotherapy 48Cloning and cell therapy 49Techniques for cell manipulation 49Cell-based drug discovery 50Advantages and limitations of cell-based assays for drug discovery 50Advantages and limitations of cell-based toxicity screening 50Quality control of cells for drug discovery 51Companies involved in cell-based drug discovery 51Drug delivery systems for cell therapy 53Intravenous delivery of stem cells 53Pharmacologically active microcarriers 53Devices for delivery of cell therapy 54Artificial cells 55Applications of artificial cells 55Cell encapsulation 55Diffusion capsule for cells 56Encapsulated cell biodelivery 56Therapeutic applications of encapsulated cells 56Nitric oxide delivery by encapsulated cells 58Implantation of microencapulated genetically modified cells 58Ferrofluid microcapsules for tracking with MRI 59Companies involved in encapsulated cell technology 59Electroporation 60Gene therapy 60Cell-mediated gene therapy 61Fibroblasts 61Chondrocyte 62Skeletal muscle cells 62Vascular smooth muscle cells 63Keratinocytes 63Hepatocytes 63Lymphocytes 63Mammalian artificial chromosomes 64In vivo tracking of cells 64Molecular imaging for tracking cells 64MRI technologies for tracking cells 65Superparamagnetic iron oxide nanoparticles as MRI contrast agents 66Visualization of gene expression in vivo by MRI 66Role of nanobiotechnology in development of cell therapy 66Cell transplantation for development of organs 67Cells transplantation and tolerance 67Strategies to improve tolerance of transplanted cells 68Encapsulation to prevent immune rejection 68Prevention of rejection of xenotransplants 68Expansion of allospecific regulatory T cells 68Removal and replacement of pathogenic cells of the body 69Therapeutic leukocytapheresis 693. Stem Cells 71Introduction 71Biology of stem cells 72Embryonic stem cells 72Growth and differentiation of ESCs 72Mechanisms of differentiation of ESCs 73Chemical regulation of stem cell differentiation 73In vitro differentiation of hESCs 73SIRT1 regulation during stem cell differentiation 73Regulation of stem cell self-renewal and differentiation 74hESCs for reprogramming human somatic nuclei 74Stem cells differentiation in the pituitary gland 74Influence of microenvironment on ESCs 75Role of genes in differentiation of ESCs 75Global transcription in pluripotent ESCs 75Role of p53 tumor suppressor gene in stem cell differentiation 76Role of Pax3 gene in stem cell differentiation 76Signaling pathways and ESC genes 76Epigenetics of hESCs 77Chromatin as gene regulator for ESC development 77Comparison of development of human and mouse ESCs 78Mechanism of regulation of stem cells for regeneration of body tissues 78Role of microenvironments in the regulation of stem cells 79Regulation and regeneration of intestinal stem cells 79Parthenogenesis and human stem cells 79Uniparental ESCs 80Bone marrow stem cells 81Hematopoietic stem cells 81Role of HSCs in the immune system 83Derivation of HSCs from ESCs 83Mesenchymal stem cells 83Multipotent adult progenitor cells 85Side population (SP) stem cells 85Differentiation of adult stem cells 86Growth and differentiation of HSCs 87Signaling pathways in the growth and differentiation of HSCs 87Mathematical modeling of differentiation of HSCs 87Role of prions in self renewal of HSCs 88Sources of stem cells 88Sources of of human embryonic stem cells 88Nuclear transfer to obtain hESCs 88Direct derivation of hESCs from embryos without nuclear transfer 89Alternative methods of obtaining hESCs 90Establishing hESC lines without destruction of embryo 90Altered nuclear transfer 91Small embryonic-like stem cells 91Advantages and disadvantages of ESCs for transplantation 92Use of ESC cultures as an alternative source of tissue for transplantation 92Spermatogonial stem cells 93Amniotic fluid as a source of stem cells 94Amniotic fluid stem cells for tissue repair and regeneration 94Generation of iPS cells from AF cells 94Placenta as source of stem cells 95Amnion-derived multipotent progenitor cells 95Placenta as a source of HSCs 96Umbilical cord as a source of MSCs 96Umbilical cord blood as source of neonatal stem cells 96Cryopreservation of UCB stem cells 97UCB as source of MSCs 98Applications of UCB 98Advantages of UCB 98Limitations of the use of UCB 99Licensing and patent disputes involving UCB 100Infections following UCB transplants 100Unanswered questions about UCB transplantation 101Companies involved in UCB banking 101UCB banking in the UK 102US national UCB banking system 103Future prospects of UCB as a source of stem cells 104Induced pluripotent stem cells derived from human somatic cells 104Characteristics of iPSCs 105DNA methylation patterns of iPS cells 105iPSCs derived from oocytes through SCNT 105iPSCs derived from skin 106iPSCs derived from blood 106Use of retroviral vectors for generation of iPSCs 107Use of non-integrating viral vectors for generation of iPSCs 107Generation of clinically relevant iPSCs 108Generation of RBCs from iPSCs 109iPSCs and disease modeling 109iPSCs for patient-specific regenerative medicine 110Concluding remarks about clinical potential of iPSCs 110Induced conditional self-renewing progenitor cells 110Sources of adult human stem cells 111Adipose tissue as a source of stem cells 111Intravenous infusion of adipose tissue derived MSCs 112iPSCs derived from adult human adipose stem cells 112Regulation of adipose stem cells differentiation 112Transforming adult adipose stem cells into other cells 113Multipotent stem-like cells derived from vascular endothelial cells 113Skin as a source of stem cells 113Controlling the maturation of embryonic skin stem cells 113Epidermal neural crest stem cells 114Follicle stem cells 114Mesenchymal stem cells in skin 115Regulation of stem cells in hair follicles 115Skin-derived precursor cells 115Stem cells in teeth 116Peripheral blood stem cells 116Spleen as a source of adult stem cells 117Search for master stem cells 117Vascular cell platform to self-renew adult HSC 117Adult stem cells vs embryonic stem cells 118Biological differences between adult and embryonic stem cells 118Neural crest stem cells from adult hair follicles 118Transdifferentiation potential of adult stem cells 119Limitations of adult stem cells 120Comparison of human stem cells according to derivation 120VENT cells 121Stem cell banking 121Stem cell technologies 122Analysis of stem cell growth and differentiation 122Tracking self-renewal and expansion of transplanted muscle stem cells 122Stem cell biomarkers 122Endoglin as a functional biomarker of HSCs 123STEMPRO? EZChek? for analysis of biomarkers of hESCs 123SSEA-4 as biomarker of MSCs 123p75NTR as a biomarker to isolate adipose tissue-derived stem cells 123Neural stem cell biomarker 124Protein expression profile as biomarker of stem cells 124Real-time PCR for quantification of protein biomarkers 124Study of stem cell pathways 125Study of stem cell genes 125Gene inactivation to study hESCs 125RNAi to study gene inactivation in hESCs 126Study of ESC development by inducible RNAi 126Targeting Induced Local Lesions in Genomes 127Homologous recombination of ESCs 127Immortalization of hESCs by telomerase 127Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease 128miRNA and stem cells 128Role of miRNAs in gene regulation during stem cell differentiation 128Influence of miRNA on stem cell formation and maintenance 129Transcriptional regulators of ESCs control miRNA gene expression 129Stem cells and cloning 130Cell nuclear replacement and cloning 130Nuclear transfer and ESCs 130Cloning from differentiated cells 131Cloning mice from adult stem cells 132Creating interspecies stem cells 132Cloned cells for transplantation medicine 133Claims of cloning of hESCs 133Cytogenetics of embryonic stem cells 134Engraftment, mobilization and expansion of stem cells 135Adipogenesis induced by adipose tissue-derived stem cells 136Antisense approach for preservation and expansion of stem cells 136Biomatrials for ESC growth 137Chemoattraction of neuronal stem cells through GABA receptor 137Enhancement of HSC engraftment by calcium-sensing receptor 137Enhancement of stem cell differentiation by Homspera 138Ex vivo expansion of human HSCs in culture 138Ex vivo expansion of MSCs 139Ex vivo expansion of UCB cells for transplantation 139Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase 139Expansion of adult stem cells by activation of Oct4 140Expansion of transduced HSCs in vivo 140Expansion of stem cells in vivo by Notch receptor ligands 140Mobilization of HSCs by growth factors 140Mobilization of stem cells by cytokines/chemokines 141Mobilization of adult human HSCs by use of inhibitors 142Mobilization of stem cells by HYC750 142Mobilization of stem cells by hyperbaric oxygen 143Mobilization by adenoviral vectors expressing angiogenic factors 143Selective mobilization of progenitor cells from bone marrow 143Selective Amplification 144Stem cell mobilization by acetylcholine receptor agonists 144Use of parathyroid hormone to increase HSC mobilzation 144Technologies for inducing differentiation of stem cells 145Generation of RBCs from hematopoietic stem cells 145Generation of multiple types of WBCs from hESCs and iPSCs 145Growth factor-induced differentiation of MAPCs 145Lineage selection to induce differentiation of hESCs 146Mechanical strain to induce MSC differentiation 146Neurotrophin-mediated survival and differentiation of hESCs 146Synthetic biology and stem cells 147Use of RNAi to expand the plasticity of autologous adult stem cells 147Use of carbohydrate molecules to induce differentiation of stem cells 148Limitations of the currently available stem cell lines in the US 148Stem cell separation 148Stem cell culture 149Culture of hMSCs 150Elimination of contaminating material in stem cell culture 150Long-term maintenance of MSC multipotency in culture 151Nanofiber scaffolds for stem cell culture 152Conversion of stem cells to functioning adipocytes 152Mass production of ESCs 152Promoting survival of dissociated hESCs 153Analysis and characterization of stem cells 153Havesting and identification of EPCs 153Labeling of stem cells 154Labeling, imaging and tracking of stem cells in vivo 154Perfluorocarbon nanoparticles to track therapeutic cells in vivo 154Project for imaging in stem cell therapy research 155Quantum dots for labeling and imaging of stem cells 155Superparamagnetic iron oxide nanoparticles for tracking MSCs 156Applications of stem cells 156Commercial development and applications of adult stem cells 157Retrodifferentiation of stem cells 157MultiStem 157Controlling the maintenance process of hematopoietic stem cells 157Self renewal and proliferation of HSCs 157Aging and rejuvenation of HSCs 158Peripheral blood stem cell transplantation 158Role of stem cells in regeneration 158Promotion of regeneration by Wnt/beta-catenin signaling 159Stem cells and human reproduction 159Expansion of spermatogonial stem cells 159Conversion of ESCs into spermatogonial stem cells 159Conversion of stem cells to oocytes 160ESCs for treatment of infertility in women 160Cloning human embryos from oocytes matured in the laboratory 161In utero stem cell transplantation 161Innovations in delivery of stem cells 162Polymeric capsules for stem cell delivery 163Immunological aspects of hESC transplantation 163Immunosuppression to prevent rejection of hESC transplants 163Histocompatibility of hESCs 163Strategies for promoting immune tolerance of hESCs 164Stem cells for organ vascularization 164Activation of EphB4 to enhance angiogenesis by EPCs 165Advantages and limitations of clinical applications of MSCs 165Biofusion by genetically engineering stem cells 166Stem cell gene therapy 166Combination of gene therapy with nuclear transfer 166Gene delivery to stem cells by artificial chromosome expression 167Genetic manipulation of ESCs 167Genetic engineering of human stem cells for enhancing angiogenesis 168HSCs for gene therapy 168Helper-dependent adenoviral vectors for gene transfer in ESCs 169Lentiviral vectors for in vivo gene transfer to stem cells 169Linker based sperm-mediated gene transfer technology 169Mesenchymal stem cells for gene therapy 169Microporation for transfection of MSCs 170Regulation of gene expression for SC-based gene therapy 170Stem cells and in utero gene therapy 170Therapeutic applications for hematopoietic stem cell gene transfer 171The future of hematopoietic stem cell gene therapy 171Stem cell pharmaceutics 171Cardiomyocytes derived from hESCs 171ESCs as source of models for drug discovery 172hESC-derived hepatocytes for drug discovery 173Pharmaceutical manipulation of stem cells 173Role of stem cells in therapeutic effects of drugs 175Stem cells for drug discovery 175Stem cells for drug delivery 176Stem cell activation for regeneration by using glucocortoids 176Toxicology and drug safety studies using ESCs versus other cells 177Future challenges for stem cell technologies 179Study of the molecular mechanism of cell differentiation 179MBD3-deficient ESC line 180In vivo study of human hemopoietic stem cells 180Stem cell biology and cancer 180Research into plasticity of stem cells from adults 181Stem cells and aging 181Activation of bone marrow stem cells into therapeutic cells 182Role of nitric oxide in stem cell mobilization and differentiation 183Stem cell genes 183Gene expression in hESCs 183The casanova gene in zebrafish 184Nanog gene 184Stem cell proteomics 185hESC phosphoproteome 186Proteomic studies of mesenchymal stem cells 186Proteomic profiling of neural stem cells 186Proteome Biology of Stem Cells Initiative 187Genomic alterations in cultured hESCs 187Hybrid embryos/cybrids for stem cell research 187Generation of patient-specific pluripotent stem cells 188Markers for characterizing hESC lines 189Switch of stem-cell function from activators to repressors 189Stem cell research at academic centers 190International Regulome Consortium 191Companies involved in stem cell technologies 191Concluding remarks about stem cells 196Challenges and future prospects of stem cell research 1974. Clinical Applications of Cell Therapy 199Introduction 199Cell therapy for hematological disorders 199Transplantation of autologous hematopoietic stem cells 199Hemophilias 199Ex vivo cell/gene therapy of hemophilia B 199Cell/gene therapy of hemophilia A 200Hematopoietic stem cell therapy for thrombocytopenia 201Stem cell transplant for sickle cell anemia 201Treatment of chronic acquired anemias 202Implantation of genetically engineered HSCs to deliver rhEpo 202Drugs acting on stem cells for treatment of anemia 202Stem cell therapy of hemoglobinopathies 203Stem cells for treatment of immunoglobulin-light chain amyloidosis 203Future prospects of cell therapy of hematological disorders 203Cell therapy for immunological disorders 204Role of dendritic cells in the immune system 204Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures 204Potential of MSCs as therapy for immune-mediated diseases 205Stem cell therapy of chronic granulomatous disease 205Stem cell therapy of X-linked severe combined immunodeficiency 206Stem cell therapy of autoimmune disorders 206Treatment of rheumatoid arthritis with stem cells 206Treatment of Crohn's disease with stem cells 207Stem cell transplants for scleroderma 207Role of T Cells in immunological disorders 208Autologous T cells from adult stem cells 208Cell therapy for graft vs host disease 209MSCs for GVHD 210Cell therapy for viral infections 210T-cell therapy for CMV 210T-cell therapy for HIV infection 211T-cell immunity by Overlapping Peptide-pulsed Autologous Cells 211Anti-HIV ribozyme delivered in hematopoietic progenitor cells 212Dendritic-cell targeted DNA vaccine for HIV 212Cell therapy of lysosomal storage diseases 212Niemann-Pick disease 213Gaucher's disease 213Fabry's disease 214Cell therapy for diabetes mellitus 214Limitations of current treatment 215Limitations of insulin therapy for diabetes mellitus 215Limitations of pancreatic transplantation 215Islet cell transplantation 216Autologous pancreatic islet cell transplantation in chronic pancreatitis 216Clinical trials of pancreatic islet cell transplants for diabetes 216Drawbacks of islet cell therapy 217Use of an antioxidant peptide to improve islet cell transplantation 217Cdk-6 and cyclin D1 enhance human beta cell replication and function 218A device for delivery of therapeutic cells in diabetes 218Monitoring of islet cell transplants with MRI 218Concluding remarks about allogeneic islet transplantation for diabetes 219Encapsulation of insulin producing cells 219Encapsulated porcine pancreatic islet cells for pancreas 219Encapsulated insulinoma cells 220Magnetocapsule enables imaging/tracking of islet cell transplants 220Islet precursor cells 221Dedifferentiation of ? cells to promote regeneration 221Pharmacological approaches for ? cell regeneration 222Xenotransplantation of embryonic pancreatic tissue 222Non-pancreatic tissues for generation of insulin-producing cells 223Exploiting maternal microchimerism to treat diabetes in the child 223Bio-artificial substitutes for pancreas 223Role of stem cells in the treatment of diabetes 224Embryonic stem cells for diabetes 224HSC transplantation to supplement immunosuppressant therapy 225Human neural progenitor cells converted into insulin-producing cells 225Insulin-producing cells derived from UCB stem cells 226iPS cells for diabetes 226Isolation of islet progenitor cells 226Pancreatic progenitor cells Expansion in vitro 227Pancreatic stem cells 227Stem cell injection into portal vein of diabetic patients 227Dendritic cell-based therapy for type 1 diabetes 228Vaccine for diabetes 228Gene therapy in diabetes 228Viral vectors for gene therapy of diabetes 229Genetically engineered dendritic cells 229Genetically altered liver cells 229Genetically modified stem cells 230Companies developing cell therapy for diabetes 230Concluding remarks about cell and gene therapy of diabetes 231Cell therapy of gastrointestinal disorders 232Inflammatory bowel disease 232Cell therapy for liver disorders 233Types of cells and methods of delivery for hepatic disorders 233Bioartificial liver 234Limitations of bioartificial liver 235Stem cells for hepatic disorders 235Deriving hepatocytes from commercially available hMSCs 236Implantation of hepatic cells derived from hMSCs of adipose tissue 236MSC derived molecules for reversing hepatic failure 236Cell-based gene therapy for liver disorders 237Transplantation of genetically modified fibroblasts 237Transplantation of genetically modified hepatocytes 237Intraperitoneal hepatocyte transplantation 238Genetically modified hematopoietic stem cells 238Use of iPSCs derived from somatic cells for liver regeneration 238Clinical applications 238Future prospects of cell-based therapy of hepatic disorders 239Cell therapy of renal disorders 239Bioartificial kidney 240Cell-based repair for vascular access failure in renal disease 240Mesangial cell therapy for glomerular disease 240Stem cells for renal disease 241Role of stem cells in renal repair 241Bone marrow stem cells for renal disease 241MSC therapy for renal disease 242Cell therapy for pulmonary disorders 242Delivery of cell therapy for pumonary disorders 242Intratracheal injection of cells for pulmonary hypoplasia 242Role of stem cells in pulmonary disorders 243Lung stem cells 243Lung tissue regeneration from stem cells 243Role of stem cells in construction of the Cyberlung 244Respiratory epithelial cells derived from UCB stem cells 244Respiratory epithelial cells derived from hESCs 244Lung tissue engineering with adipose stromal cells 245Cell-based tissue-engineering of airway 245Pulmonary disorders that can be treatable with stem cells 245Acute lung injury and ARDS treated with MSCs 246Bronchopulmonary dysplasia treated with MSCs 247Chronic obstructive pulmonary disease treated with MSCs 247Cystic fibrosis treatment with genetically engineered MSCs 247Lung regeneration by integrin ?6?4-expressing alveolar epithelial cell 248Pulmonary arterial hypertension treatment with EPCs 248Cell therapy for disorders of bones and joints 249Repair of fractures and bone defects 249Adult stem cells for bone grafting 250Cell therapy for osteonecrosis 250Cell therapy for cervical vertebral interbody fusion 250ESCs for bone repair 251Intrauterine use of MSCs for osteogenesis imperfecta 251In vivo bone engineering as an alternative to cell transplantation 251MSCs for repair of bone defects 251MSCs for repair of bone fractures 254Osteocel 255Stem cells for repairing skull defects 255Stem cell-based bone tissue engineering 255Spinal fusion using stem cell-based bone grafts 256Osteoarthritis and other injuries to the joints 257Mosaicplasty 257Autologous cultured chondrocytes 257Autologous intervertebral disc chondrocyte transplantation 258Cartilage repair by genetically modified fibroblasts expressing TGF-? 259Generation of cartilage from stem cells 260Role of cell therapy in repair of knee cartilage injuries 261Role of cells in the repair of anterior cruciate ligament injury 263Autologous tenocyte implantation in rotator cuff injury repair 263Platelet injection for tennis elbow 264Cell therapy of rheumatoid arthritis 264Cell therapy for diseases of the eye 265Cell therapy for corneal repair 265Stem cell therapy for limbal stem cell deficiency 266Role of stem cells in fibrosis following eye injury 267Stem cell transplantation for radiation sickness 267MSCs for treatment of radiation damage to the bone 267MSCs for regeneration of ovaries following radiotherapy damage 268Cell therapy for regeneration 268Stem cells for regenerating organs 268Umbilical cord blood for regeneration 269Role of stem cells in regeneration of esophageal epithelium 269Cell therapy for regeneration of muscle wasting 269Wound healing: skin and soft tissue repair 270Cells to form skin substitutes for healing ulcers 271CellSpray for wound repair 271Cell therapy for burns 272Closure of incisions with laser guns and cells 273Follicular stem cells for skin and wound repair 273Reprogramming autologous stem cells for wound regeneration 274Role of amniotic fluid MSCs in repair of fetal wounds 274Genetically engineered keratinocytes for wound repair 274MSCs for wound healing 275Regeneration of aging skin by adipose-derived stem cells 275Repair of aging skin by injecting autologous fibroblasts 275Role of cells in tissue engineering and reconstructive surgery 275Stem cells for tissue repair 275Scaffolds for tissue engineering 276Improving vascularization of engineered tissues 276Enhancing vascularization by combining cell and gene therapy 277Choosing cells for tissue engineering 277ESCs vs adult SCs for tissue engineering 277Use of adult MSCs for tissue engineering 278Nanobiotechnology applied to cells for tissue engineering 279Stem cells for tissue engineering of various organs 279Engineering of healthy living teeth from stem cells 279Adipose tissue-derived stem cells for breast reconstruction 280Improving tissue engineering of bone by MSCs 281Intra-uterine repair of congenital defects using amniotic fluid MSCs 281Cell-based tissue engineering in genitourinary system 282Urinary incontinence 282Tissue engineering of urinary bladder 283Label retaining urothelial cells for bladder repair 283MSCs for bladder repair 284Tissue-engineering of urethra using autologous cells 284Repair of the pelvic floor with stem cells from the uterus 284Reconstruction of vagina from stem cells 285Facial skin regeneration by stem cells as an alternative to face transplant 285Reconstruction of cartilage for repair of craniofacial defects 285Cell therapy for rejuvenation 286Cell therapy for performance enhancement in sports 286Application of stem cells in veterinary medicine 286Use of stem cells to repair tendon injuries 286Stem cells for spinal cord injury in dogs 2875. Cell Therapy for Cardiovascular Disorders 289Introduction to cardiovascular disorders 289Limitations of current therapies for myocardial ischemic disease 289Types of cell therapy for cardiovascular disorders 289Cell-mediated immune modulation for chronic heart disease 290Human cardiovascular progenitor cells 291Inducing the proliferation of cardiomyocytes 291Pericardial origin of colony-forming units 292Role of the SDF-1-CXCR4 axis in stem cell therapies for myocardial ischemia 292Role of splenic myocytes in repair of the injured heart 292Reprogramming of fibroblasts into functional cardiomyocytes 293Small molecules to enhance myocardial repair by stem cells 293Cell therapy for atherosclerotic coronary artery disease 293MyoCell™ (Bioheart) 294Cardiac stem cells 294Cardiomyocytes derived from epicardium 295Methods of delivery of cells to the heart 296Cellular cardiomyoplasty 296IGF-1 delivery by nanofibers to improve cell therapy for MI 296Non-invasive delivery of cells to the heart by Morph®guide catheter 296Cell therapy for cardiac revascularization 297Transplantation of cardiac progenitor cells for revascularization of myocardium 297Stem cells to prevent restenosis after coronary angioplasty 297Role of cells in cardiac tissue repair 298Modulation of cardiac macrophages for repair of infarct 298Transplantation of myoblasts for myocardial infarction 298Patching myocardial infarction with fibroblast culture 299Cardiac repair with myoendothelial cells from skeletal muscle 299Myocardial tissue engineering 300Role of stem cells in repair of the heart 301Role of stem cells in cardiac regen

To order this report:Biological Therapy Industry: Cell Therapy - Technologies, Markets and Companies

More  Market Research Report

Check our  Industry Analysis and Insights

 

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

Go here to see the original:
Cell Therapy - Technologies, Markets and Companies

Read More...

‘Personalized medicine’ gets $67.5M research boost

February 1st, 2012 12:49 am

The federal government is pledging up to $67.5 million for research into "personalized medicine," which tailors treatment to a patient's genetics and environment.

The funds will flow through Genome Canada, the Cancer Stem Cell Consortium and the Canadian Institutes of Health Research, the federal government's health research agency.

Federal Health Minister Leona Aglukkaq and Minister of State for Science Gary Goodyear made the announcement at the University of Ottawa's health campus Tuesday.

The field of personalized medicine is touted as having the potential to transform the way patients are treated. It looks at the genetic makeup of a person, the patient's environment and the exact course of a particular disease so that an appropriate and effective treatment can be tailored for that individual.

The idea is to move from a one-size-fits-all approach to one that is designed for a specific person and relies on the genetic signatures, or biomarkers, of both the patient and the disease.

Proponents of personalized medicine say it is likely to change the way drugs are developed, how medicines are prescribed and generally how illnesses are managed. They say it will shift the focus in health care from reaction to prevention, improve health outcomes, make drugs safer and mean fewer adverse drug reactions, and reduce costs to health-care systems.

"The potential to understand a person's genetic makeup and the specific character of their illness in order to best determine their treatment will significantly improve the quality of life for patients and their families and may show us the way to an improved health-care system and even save costs in certain circumstances," Aglukkaq said in a news release.

Research projects could last four years

The sequencing of the human genome paved the way for personalized medicine and there have been calls for more research funding so that the discoveries in laboratories can be translated further into the medical field so they will benefit patients more.

Identifying a person's genetic profile, for example, could then indicate a susceptibility to a certain disease, if the biomarkers of that disease have also been discovered. If people know they are genetically at risk of an illness they can take actions to prevent it, and their health-care providers can monitor for it.

Cancer patients could be pre-screened to determine if chemotherapy would work for them, which could not only save a lot of money on expensive treatments but also prevent pain and suffering for patients.

Genome Canada is leading the research initiative, in collaboration with Cancer Stem Cell Consortium and CIHR which on Tuesday launched its Personalized Medicine Signature Initiative. CIHR is committing up to $22.5 million to the large-scale initiative with the other two partners, but it will be providing more funding for other projects under its personalized medicine program.

The research projects are aiming to bring together biomedical, clinical, population health, health economics, ethics and policy researchers to identify areas that are best suited to personalized medicine.

Oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer’s disease are all considered to be areas that hold promise for personalized medicine.

Funding will also go to projects that are aimed at developing more evidence-based and cost-effective approaches to health care.

Researchers can get up to four years of funding, but 50 per cent of their requested funding must be matched from another source, such as a provincial government or from the academic or private sectors.

Genome Canada, CIHR and the cancer consortium will invest a maximum of $5 million in each individual project.

The successful applicants for the $67.5 million worth of funding won't be announced until December.

Continue reading here:
'Personalized medicine' gets $67.5M research boost

Read More...

Baby Stem Cell Franken-food – Pepsi, Coke, Nestle, Starbucks

January 31st, 2012 8:25 pm

30-01-2012 08:31 US: Senomyx's Fake Flavors http://www.corpwatch.org China: Businesses Sell Aborted Babies as Stamina Booster Pills http://www.lifenews.com Pepsi Uses Aborted Fetal Cells In Flavor Enhancers govtslaves.info Products and Companies that use Aborted Fetuses brie-hoffman.hubpages.com Senomyx Website http://www.senomyx.com

View original post here:
Baby Stem Cell Franken-food - Pepsi, Coke, Nestle, Starbucks

Read More...

Stanford scientists bypass stem cells to create nervous system cells

January 31st, 2012 8:25 pm

Bypassing stem cells, mouse skin cells have been converted directly into cells that become the three main parts of the animal's nervous system, according to new research at the Stanford University School of Medicine.

The startling success of this method seems to refute the idea that "pluripotency" -- the ability of stem cells to become nearly any cell in the body -- is necessary for a cell to transform from one cell type to another.

It raises the possibility that embryonic stem cell research, as well as a related technique called "induced pluripotency," could be supplanted by a more direct way of generating cells for therapy or research.

"Not only do these cells appear functional in the laboratory, they also seem to be able to integrate ... in an animal model," said lead author and graduate student Ernesto Lujan.

The study was published online Jan. 30 in the Proceedings of the National Academy of Sciences.

The finding implies that it may one day be possible to generate a variety of neural-system cells for transplantation that would perfectly match a human patient.

While much research has been devoted to harnessing the potential of embryonic stem cells, taking those cells from an embryo and then implanting them in a patient could prove difficult because they would not match genetically.

The Stanford team is working to replicate the work with skin cells from adult mice and humans.

But Lujan emphasized that

much more research is needed before any human transplantation experiments could be conducted.

In the meantime, however, the ability to quickly and efficiently generate cells -- grown in mass quantities in the laboratory, and maintained over time -- will be valuable in disease and drug-targeting studies.

Contact Lisa M. Krieger at 408-920-5565.

Go here to see the original:
Stanford scientists bypass stem cells to create nervous system cells

Read More...

Stem Cells May Further Hepatitis C Research

January 31st, 2012 8:25 pm

TUESDAY, Jan. 31 (HealthDay News) -- Using stem cells to create liver-like cells for laboratory research may advance efforts to find out why people respond differently to hepatitis C infection, scientists say.

It's not clear why some people are resistant to hepatitis C, while others are highly susceptible to the infectious disease that can cause liver inflammation and organ failure.

Studying liver cells from various people could reveal genetic factors behind these different responses, but liver cells are difficult to obtain and to grow in a lab dish.

Now, U.S. researchers have found a way to create liver-like cells from induced pluripotent stem cells (iPSCs), which are made from body tissues rather than embryos. These liver-like cells can then be infected with hepatitis C.

The research was published Jan. 30 in the journal Proceedings of the National Academy of Sciences.

It's the first time that scientists have been able to establish an infection in iPSC-derived cells. The technique was developed by a team from MIT, Rockefeller University and the Medical College of Wisconsin.

Along with benefiting hepatitis C research, the new technique may eventually have a role in personalized medicine, the researchers said in a MIT news release. By testing the effectiveness of different drugs on tissues derived from a patient, doctors could customize therapy for that patient, they said.

More information

The American Academy of Family Physicians has more about hepatitis C.

See the article here:
Stem Cells May Further Hepatitis C Research

Read More...

Skin cells turned into neural precusors, bypassing stem-cell stage

January 31st, 2012 8:19 pm

ScienceDaily (Jan. 30, 2012) — Mouse skin cells can be converted directly into cells that become the three main parts of the nervous system, according to researchers at the Stanford University School of Medicine. The finding is an extension of a previous study by the same group showing that mouse and human skin cells can be directly converted into functional neurons.

The multiple successes of the direct conversion method could refute the idea that pluripotency (a term that describes the ability of stem cells to become nearly any cell in the body) is necessary for a cell to transform from one cell type to another. Together, the results raise the possibility that embryonic stem cell research and another technique called "induced pluripotency" could be supplanted by a more direct way of generating specific types of cells for therapy or research.

This new study, published online Jan. 30 in the Proceedings of the National Academy of Sciences, is a substantial advance over the previous paper in that it transforms the skin cells into neural precursor cells, as opposed to neurons. While neural precursor cells can differentiate into neurons, they can also become the two other main cell types in the nervous system: astrocytes and oligodendrocytes. In addition to their greater versatility, the newly derived neural precursor cells offer another advantage over neurons because they can be cultivated to large numbers in the laboratory -- a feature critical for their long-term usefulness in transplantation or drug screening.

In the study, the switch from skin to neural precursor cells occurred with high efficiency over a period of about three weeks after the addition of just three transcription factors. (In the previous study, a different combination of three transcription factors was used to generate mature neurons.) The finding implies that it may one day be possible to generate a variety of neural-system cells for transplantation that would perfectly match a human patient.

"We are thrilled about the prospects for potential medical use of these cells," said Marius Wernig, MD, assistant professor of pathology and a member of Stanford's Institute for Stem Cell Biology and Regenerative Medicine. "We've shown the cells can integrate into a mouse brain and produce a missing protein important for the conduction of electrical signal by the neurons. This is important because the mouse model we used mimics that of a human genetic brain disease. However, more work needs to be done to generate similar cells from human skin cells and assess their safety and efficacy."

Wernig is the senior author of the research. Graduate student Ernesto Lujan is the first author.

While much research has been devoted to harnessing the pluripotency of embryonic stem cells, taking those cells from an embryo and then implanting them in a patient could prove difficult because they would not match genetically. An alternative technique involves a concept called induced pluripotency, first described in 2006. In this approach, transcription factors are added to specialized cells like those found in skin to first drive them back along the developmental timeline to an undifferentiated stem-cell-like state. These "iPS cells" are then grown under a variety of conditions to induce them to re-specialize into many different cell types.

Scientists had thought that it was necessary for a cell to first enter an induced pluripotent state or for researchers to start with an embryonic stem cell, which is pluripotent by nature, before it could go on to become a new cell type. However, research from Wernig's laboratory in early 2010 showed that it was possible to directly convert one "adult" cell type to another with the application of specialized transcription factors, a process known as transdifferentiation.

Wernig and his colleagues first converted skin cells from an adult mouse to functional neurons (which they termed induced neuronal, or iN, cells), and then replicated the feat with human cells. In 2011 they showed that they could also directly convert liver cells into iN cells.

"Dr. Wernig's demonstration that fibroblasts can be converted into functional nerve cells opens the door to consider new ways to regenerate damaged neurons using cells surrounding the area of injury," said pediatric cardiologist Deepak Srivastava, MD, who was not involved in these studies. "It also suggests that we may be able to transdifferentiate cells into other cell types." Srivastava is the director of cardiovascular research at the Gladstone Institutes at the University of California-San Francisco. In 2010, Srivastava transdifferentiated mouse heart fibroblasts into beating heart muscle cells.

"Direct conversion has a number of advantages," said Lujan. "It occurs with relatively high efficiency and it generates a fairly homogenous population of cells. In contrast, cells derived from iPS cells must be carefully screened to eliminate any remaining pluripotent cells or cells that can differentiate into different lineages." Pluripotent cells can cause cancers when transplanted into animals or humans.

The lab's previous success converting skin cells into neurons spurred Wernig and Lujan to see if they could also generate the more-versatile neural precursor cells, or NPCs. To do so, they infected embryonic mouse skin cells -- a commonly used laboratory cell line -- with a virus encoding 11 transcription factors known to be expressed at high levels in NPCs. A little more than three weeks later, they saw that about 10 percent of the cells had begun to look and act like NPCs.

Repeated experiments allowed them to winnow the original panel of 11 transcription factors to just three: Brn2, Sox2 and FoxG1. (In contrast, the conversion of skin cells directly to functional neurons requires the transcription factors Brn2, Ascl1 and Myt1l.) Skin cells expressing these three transcription factors became neural precursor cells that were able to differentiate into not just neurons and astrocytes, but also oligodendrocytes, which make the myelin that insulates nerve fibers and allows them to transmit signals. The scientists dubbed the newly converted population "induced neural precursor cells," or iNPCs.

In addition to confirming that the astrocytes, neurons and oligodendrocytes were expressing the appropriate genes and that they resembled their naturally derived peers in both shape and function when grown in the laboratory, the researchers wanted to know how the iNPCs would react when transplanted into an animal. They injected them into the brains of newborn laboratory mice bred to lack the ability to myelinate neurons. After 10 weeks, Lujan found that the cells had differentiated into oligodendroytes and had begun to coat the animals' neurons with myelin.

"Not only do these cells appear functional in the laboratory, they also seem to be able to integrate appropriately in an in vivo animal model," said Lujan.

The scientists are now working to replicate the work with skin cells from adult mice and humans, but Lujan emphasized that much more research is needed before any human transplantation experiments could be conducted. In the meantime, however, the ability to quickly and efficiently generate neural precursor cells that can be grown in the laboratory to mass quantities and maintained over time will be valuable in disease and drug-targeting studies.

"In addition to direct therapeutic application, these cells may be very useful to study human diseases in a laboratory dish or even following transplantation into a developing rodent brain," said Wernig.

In addition to Wernig and Lujan, other Stanford researchers involved in the study include postdoctoral scholars Soham Chanda, PhD, and Henrik Ahlenius, PhD; and professor of molecular and cellular physiology Thomas Sudhof, MD.

The research was supported by the California Institute for Regenerative Medicine, the New York Stem Cell Foundation, the Ellison Medical Foundation, the Stinehart-Reed Foundation and the National Institutes of Health.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Stanford University Medical Center. The original article was written by Krista Conger.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

E. Lujan, S. Chanda, H. Ahlenius, T. C. Sudhof, M. Wernig. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proceedings of the National Academy of Sciences, 2012; DOI: 10.1073/pnas.1121003109

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

More here:
Skin cells turned into neural precusors, bypassing stem-cell stage

Read More...

Stem cells offer hope for blind – Video

January 31st, 2012 6:04 pm

24-01-2012 12:40 Mon, Jan 23: It's an experimental breakthrough treatment for macular degeneration. Jennifer Tryon explains how embryonic stem cells helped two blind people see again.

Read the rest here:
Stem cells offer hope for blind - Video

Read More...

Health Travel Technologies Signs Patient Referral and Management Licensing Partnership with Orbicare Latin American …

January 31st, 2012 6:03 pm

Orbicare signs with the Health Travel Technologies global patient referral application to enable millions of patients access to the best, most affordable medical care throughout Latin America and Europe.

San Francisco, California (PRWEB) January 31, 2012

Few would argue that the US health care system is sick, and physician-founded Orbicare of Miami is betting that Silicon Valley's Health Travel Technologies (HTT) has the cure with its global patient referral application.

The partnership between Orbicare and Health Travel Technologies connects US patients with international doctors like never before, saving thousands on the cost of necessary and cosmetic medical, dental and surgical care.

HTT is the creator of Inpatra™, the world’s most comprehensive global patient referral and management application. HTT has signed a licensing agreement with Orbicare, a leader in international patient referral, to host its comprehensive portfolio of medical services.

The partnership will provide English- and Spanish-speaking US patients and employers with high quality health care alternatives across Latin America and Europe, including medical and dental travel programs in Argentina, Costa Rica, Panama, Spain and Turkey.

“HTT helps international health care networks work directly with US patients and employers to provide much needed access to affordable health care” said Health Travel Technologies CEO Herb Stephens.

“In addition to high quality, high value medical care, an added bonus for American patients and employers is the proximity and safety of the Orbicare health care network,” said Stephens.

“Orbicare searched for the right partner for more than a year,” says Teresa Arenas, Chief Operations Officer for Orbicare. “We chose HTT for its comprehensive technology, unmatched experience and dedicated people.

“The Inpatra™ international patient referral and management application provides Orbicare with the hosted business processes we need, so that we can focus our resources on our strengths: providing personalized, quality medical services to US patients and employer benefits plans, especially during this time of rapid expansion.”

HTT is the largest technology and services company in the health information technology space, processing more than 1 million international travelers representing more than $500 million in financial transactions per year, with health travel representing double digit year-over-year growth.

About Orbicare

The regional Orbicare provider network features state-of-the-art medical centers and board-certified specialists in Panama, Spain, Argentina, Turkey, Costa Rica, El Salvador, the Dominican Republic and Colombia.

Physician-founded, Orbicare is distinguished among medical services providers by its expert management team of doctors, employer benefits specialists, and hospital administrators.

Orbicare’s member hospitals provide comprehensive medical care including bariatric and metabolic surgery, dental and orthodontic surgery, oncology, orthopedic and sports medicine, addiction treatment, cosmetic plastic surgery, cardiovascular intervention, and adult stem cell treatment for chronic disease.

Orbicare provides full-service medical benefits programs to individual patients as well as self-ensured employers.

About Medical Travel

The practice of medical travel, or medical tourism, continues to garner considerable attention as a growing number of U.S. employers, consumers and other stakeholders explore cost effective health care options for their organizations.

Experts currently estimate the size of the medical tourism market to reach $100 Billion by 2012. According to HTT CEO Herb Stephens, this increased volume creates a significant issue for international health care providers servicing an international patient base.

A MarketWatch-published Brief by the non-profit National Business Group Health (NGBH) underscores the need for an infrastructure to accommodate the anticipated growth in health travel.

The NGBH identifies innovative and forward-thinking solutions to health care and benefit issues facing large employers, a group that is rapidly adopting medical travel as a key cost-saving solution to growing health care coverage costs.

“The superb level of health care in Orbicare’s provider network throughout Latin America is indisputable," said Stephens. "The question now is how increasing patient volumes can be effectively managed while maintaining high quality service, and keeping the doctor and patient relationship at the center of it all."

About Health Travel Technologies

A technology and services company, HTT operates and licenses the award-winning Inpatra™ platform specifically developed to handle the many demands of health travel – from patient referral through post-op patient follow-up.

”We enable hospitals, physician networks and facilitators like Orbicare to create high-touch, high-efficiency patient management operations,” said HTT Chief Technology Officer Alex Marxer. “Our award-winning patient referral and management application connects the world’s patients and doctors like never before.”

Founded in 2006, and headquartered in San Francisco, California, with operations in San Diego California, Health Travel Technologies, a subsidiary of Health Travel Guides, is a privately held company.

Health Travel Foundation is a non-profit organization dedicated to providing quality care abroad to people who are unable to afford health care procedures or services.

###

Nishant Bagadia
Health Travel Technologies
(415) 651-4395
Email Information

Read the original:
Health Travel Technologies Signs Patient Referral and Management Licensing Partnership with Orbicare Latin American ...

Read More...

Harper government invests in personalized medicine

January 31st, 2012 6:02 pm

Public release date: 31-Jan-2012
[ | E-mail | Share ]

Contact: Adele Blanchard
ablanchard@cihr.gc.ca
613-946-3308
Canadian Institutes of Health Research

This press release is available in French.

Ottawa, Ontario -- The Harper Government today announced an important investment that will help Canadians in getting more effective treatments and make the healthcare system more sustainable through personalized medicine. The announcement was made by the Honourable Leona Aglukkaq, Minister of Health, and the Honourable Gary Goodyear, Minister of State for Science and Technology.

"Our Government is committed to improving the quality of life of Canadians," Minister Aglukkaq said. "The potential to understand a person's genetic makeup and the specific character of their illness in order to best determine their treatment will significantly improve the quality of life for patients and their families and may show us the way to an improved health care system and even save costs in certain circumstances."

Personalized medicine offers the potential to transform the delivery of healthcare to patients. Healthcare will evolve from a reactive "one-size-fits-all" system towards a system of predictive, preventive, and precision care. Areas in which personalized approaches are particularly promising include oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer's disease. In all of these fields, and others, a personalized molecular medicine approach is expected to lead to better health outcomes, improved treatments, and reduction in toxicity due to variable or adverse drug responses. For example, cancer patients would be screened to identify those for whom chemotherapy would be ineffective. In addition to saving on the costs of expensive drug treatments, this personalized treatment would prevent a great deal of suffering, while identifying and initiating earlier treatments that would be more effective.

"I applaud Genome Canada and the CIHR for their leadership in supporting research in personalized medicine," said Minister Goodyear. "Innovative approaches like these lead to significant health benefits, enhance our knowledge within the medical arena and can be commercialized to help so many others worldwide."

###

Genome Canada is leading the landmark research competition, with significant collaboration from the Canadian Institutes of Health Research (CIHR) and the Cancer Stem Cell Consortium (CSCC). To qualify for funding, researchers must obtain matching funding that at is least equal to that provided through the competition. Matching funding is typically derived from provincial, academic, private sector or international sources.

Fact Sheet

Further information:

Cailin Rodgers
Office of the Honourable Leona Aglukkaq
Federal Minister of Health
613-957-0200

Stephanie Thomas
Special Assistant (Communications)
Office of the Honourable Gary Goodyear
Minister of State (Science and Technology)
613-960-7728

David Coulombe
Media Relations
Canadian Institutes of Health Research
613-941-4563

Marlene Orton
Director, Media Relations
Genome Canada
613-751-4460 x119
BlackBerry: 613-295-1476

The Canadian Institutes of Health Research (CIHR) is the Government of Canada's health research investment agency. CIHR's mission is to create new scientific knowledge and to enable its translation into improved health, more effective health services and products, and a strengthened Canadian health care system. Composed of 13 Institutes, CIHR provides leadership and support to more than 14,100 health researchers and trainees across Canada. http://www.cihr-irsc.gc.ca

Genome Canada is a non-profit corporation employing an innovative business model based on funding and managing large-scale, multidisciplinary, internationally peer-reviewed genomics research projects in areas such as agriculture, forestry, fisheries, the environment and human health. For more information, visit http://www.genomecanada.ca

The Cancer Stem Cell Consortium is a not-for-profit corporation that was incorporated in 2007 to coordinate an international strategy for cancer stem cell research and related translational activities. For more information, visit http://www.cancerstemcellconsortium.ca


[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

View original post here:
Harper government invests in personalized medicine

Read More...

'Personalized medicine' gets $67.5M research boost

January 31st, 2012 6:02 pm

The federal government is pledging up to $67.5 million for research into "personalized medicine," which tailors treatment to a patient's genetics and environment.

The funds will flow through Genome Canada, the Cancer Stem Cell Consortium and the Canadian Institutes of Health Research, the federal government's health research agency.

Federal Health Minister Leona Aglukkaq and Minister of State for Science Gary Goodyear made the announcement at the University of Ottawa's health campus Tuesday.

The field of personalized medicine is touted as having the potential to transform the way patients are treated. It looks at the genetic makeup of a person, the patient's environment and the exact course of a particular disease so that an appropriate and effective treatment can be tailored for that individual.

The idea is to move from a one-size-fits-all approach to one that is designed for a specific person and relies on the genetic signatures, or biomarkers, of both the patient and the disease.

Proponents of personalized medicine say it is likely to change the way drugs are developed, how medicines are prescribed and generally how illnesses are managed. They say it will shift the focus in health care from reaction to prevention, improve health outcomes, make drugs safer and mean fewer adverse drug reactions, and reduce costs to health-care systems.

"The potential to understand a person's genetic makeup and the specific character of their illness in order to best determine their treatment will significantly improve the quality of life for patients and their families and may show us the way to an improved health-care system and even save costs in certain circumstances," Aglukkaq said in a news release.

Research projects could last four years

The sequencing of the human genome paved the way for personalized medicine and there have been calls for more research funding so that the discoveries in laboratories can be translated further into the medical field so they will benefit patients more.

Identifying a person's genetic profile, for example, could then indicate a susceptibility to a certain disease, if the biomarkers of that disease have also been discovered. If people know they are genetically at risk of an illness they can take actions to prevent it, and their health-care providers can monitor for it.

Cancer patients could be pre-screened to determine if chemotherapy would work for them, which could not only save a lot of money on expensive treatments but also prevent pain and suffering for patients.

Genome Canada is leading the research initiative, in collaboration with Cancer Stem Cell Consortium and CIHR which on Tuesday launched its Personalized Medicine Signature Initiative. CIHR is committing up to $22.5 million to the large-scale initiative with the other two partners, but it will be providing more funding for other projects under its personalized medicine program.

The research projects are aiming to bring together biomedical, clinical, population health, health economics, ethics and policy researchers to identify areas that are best suited to personalized medicine.

Oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer’s disease are all considered to be areas that hold promise for personalized medicine.

Funding will also go to projects that are aimed at developing more evidence-based and cost-effective approaches to health care.

Researchers can get up to four years of funding, but 50 per cent of their requested funding must be matched from another source, such as a provincial government or from the academic or private sectors.

Genome Canada, CIHR and the cancer consortium will invest a maximum of $5 million in each individual project.

The successful applicants for the $67.5 million worth of funding won't be announced until December.

The rest is here:
'Personalized medicine' gets $67.5M research boost

Read More...

Army’s New Weight-Loss Plan: Transplant Soldiers With Extra Fat

January 31st, 2012 5:59 pm

Just last week, military brass vowed that the force of the future would be “smaller and leaner.” Apparently, the Army’s taking that pretty damn literally. They want smaller, leaner soldiers. Their best idea to do it? Give GIs transplants of extra fat cells.

Seriously. In the Army’s latest round of small-business research awards, they’ve green-lit a proposal to manufacture transplantable brown fat cells, all in an effort to catalyze rapid weight loss. Portlier soldiers, you might recall, are turning into a major dilemma for top brass. An estimated 75 percent of today’s young Americans are either too fat, too sickly or too dumb to serve. The Army’s even overhauled their fitness program, in part to accommodate softer recruits, by swapping long runs and grueling drills for yoga and calisthenics.

Leg lifts and downward dogs, however, don’t offer much of a calorie-burning boost. Brown fat tissue, however, does. At first glance, the idea of adding fat to get rid of fat doesn’t exactly add up. After all, thousands of Americans dole out mad cash to have flab sucked out, not put back in.

The distinction comes down to varieties of fat: Humans carry pockets of conventional fat, or white adipose tissue. They also carry brown adipose tissue. And recent research has confirmed that the stuff’s pretty damn special: It burns a ton of calories — around 250 calories over three hours in one study group — and actually sucks energy out of conventional fat cells to fuel its fire. Research even suggests that additional pockets of brown fat can be created by exercise.

The Army, however, would rather see soldiers drop pounds like the Real Housewives — with as little effort as possible. They’re funding a team at the University of Boston to “generate human [brown adipose tissue]” for subsequent human transplantation. “Obesity and its associated metabolic complications…are becoming increasingly prevalent in military personnel,” the Army’s research award notes. “Increasing [brown fat] by about 50 grams in obese patients could induce strong weight loss and improve metabolic status.”

Researchers plan to isolate a brown adipose progenitor cell — cells that, similarly to stem cells, are able to differentiate into more specific types — and then generate additional brown adipose cells in the lab. From there, they’d be able to offer “transplantation therapy” to portly personnel.

Of course, plenty of uncertainty about brown fat’s promise still lingers. For one, researchers aren’t sure whether appetite’s increase in conjunction with brown fat stores, keeping weight in stasis. And they don’t know how brown fat affects metabolism and weight loss in the long-term.

But if brown fat really can catalyze weight loss and permanently boost the body’s own metabolic rate, military personnel are hardly the only ones who’d line up for treatment. And civilian companies have already taken note: One Boston company, Ember Therapeutics, recently raised $34 million in capital funding to investigate pharmaceuticals that’d convert white fat to brown.

That said, fat losses aren’t synonymous with fitness gains. In other words, the soldiers of the future might very well be smaller and leaner. But without rigorous exercise, they’ll still, sadly, totally suck at CrossFit.

Photo: Courtesy of Out of Regs

See the article here:
Army’s New Weight-Loss Plan: Transplant Soldiers With Extra Fat

Read More...

Hopes rise on treating spinal injuries with iPS cells transplant

January 31st, 2012 2:04 am

Untreatable conditions can be helped with reprogrammed adult stem cells

In just two years, the celebrated adult stem cell researcher Shinya Yamanaka hopes that clinical trials will begin on curing the once-untreatable spinal injuries with the help of “reprogrammed” adult cells or ‘induced pluripotent stem' (iPS) cells.

Animal trials have shown promising results of transplanting iPS cells to treat paralytic spinal injury, said Professor Yamanaka, delivering a lecture on “New Era of Medicine with iPS Cells” here on Monday.

The lecture was organised as part of the Cell Press-TNQ India Distinguished Lectureship Series.

Prof. Yamanaka, who started his career as a physician 25 years ago and “tried to be an orthopaedic surgeon”, said: “I soon realised I was not so good at surgery. I also realised that even a good surgeon can't help many patients suffering from untreatable diseases and injuries.”

This inspired him to change his career and get back to studying “basic medicine”.

That's where he “met” the iPS cell, which led him to his major scientific breakthrough in 2007 allowing him to “reprogramme” adult human skin cells into embryonic-like stem cells.

The iPS cells have revolutionised research on regenerative medicine: they are free from debates over ethics — often raised in the use of human embryos — and reduce the risk of tissue rejection after transplant. Once established, these cells can be used to elucidate disease mechanisms and to screen drugs.

But creating these cells is both time and money-consuming, he said.

It costs as much as U.S. $ 1 million to treat just one patient, and takes six to eight months to generate, expand and induce differentiation in iPS cells.

“In the case of spinal injuries, we have to transplant the cells within a month after the injury.

“To overcome this, we think it makes sense to create and maintain an iPS cell bank from healthy individuals,” he said.

The risk of rejection by an individual's immune system can be minimised by matching donors with HLA (human leucocyte antigen), a form of “blood type” for human cells.

In Japan, for instance, just 75 unique HLA homozygotes would match 80 per cent of the population, he explained.

Prof. Yamanaka, who was awarded the Albert Lasker Prize in 2009 and the Wolf Prize in 2011, later answered questions from budding biologists and veteran scientists in the audience.

He will speak next in Chennai on February 1 and New Delhi on February 3 as part of the lectureship series.

Here is the original post:
Hopes rise on treating spinal injuries with iPS cells transplant

Read More...

FASEB SRC Announces Conference Registration Open for: Skeletal Muscle Satellite and Stem Cells

January 31st, 2012 2:04 am

Public release date: 30-Jan-2012
[ | E-mail | Share ]

Contact: Emily Benson
SRC@faseb.org
301-634-7010
Federation of American Societies for Experimental Biology

Bethesda, MD ? The Federation of American Societies for Experimental Biology (FASEB) announces the opening of registration for the Science Research Conference (SRC): Skeletal Muscle Satellite and Stem Cells.

This conference will take place August 12-17, 2012 in Lucca, Italy. The aim of the conference is to highlight recent advances pertaining to the regulatory mechanisms of myogenic stem cell and progenitor cell populations (such as satellite cells) and their role in growth, regeneration, and therapeutics. This meeting represents the only conference that focuses exclusively on muscle satellite and stem cell populations. Sessions will address: epigenetic and post-transcriptional control of satellite cells, non-myogenic cells in muscle that influence satellite cell biology, biology of satellite cells in the head muscles, satellite cell quiescence, activation and self-renewal, the molecular control of myogenic lineage progression and differentiation, satellite cells in growth and hypertrophy, and satellite cells in aging and disease. Poster sessions will feature these and related topics. Importantly, the participants of this conference will represent interdisciplinary groups that will provide a comprehensive analysis and integration of recent discoveries for the field. The conference will provide collaborative interactions in an attempt to promote future advancements and translational initiatives directed toward the treatment and cure of patients with myopathic diseases.

###

Since 1982, FASEB SRC has offered a continuing series of inter-disciplinary exchanges that are recognized as a valuable complement to the highly successful society meetings. Divided into small groups, scientists from around the world meet intimately and without distractions to explore new approaches to those research areas undergoing rapid scientific changes.

In recent years, the SRC series has expanded into non-summer months. To better enhance the SRC series and allow for future expansion of conferences, FASEB's Office of Scientific Meetings and Conferences recently changed the SRC name from Summer Research Conferences to Science Research Conferences.

FASEB SRC has announced a total of 36 SRCs in 2012, spanning from June through October. To register for an SRC, view preliminary programs, or find a listing of all our 2012 SRCs, please visit http://www.faseb.org/SRC.

Additionally, in efforts to continue expanding the SRC series, potential organizers are encouraged to contact SRC staff at SRC@faseb.org. Proposal guidelines can be found by clicking "Submit a Proposal" on our website at http://www.faseb.org/SRC.

FASEB is composed of 26 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. Celebrating 100 Years of Advancing the Life Sciences in 2012, FASEB is rededicating its efforts to advance health and well-being by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.


[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read this article:
FASEB SRC Announces Conference Registration Open for: Skeletal Muscle Satellite and Stem Cells

Read More...

ImmunoCellular Therapeutics To Deliver Presentation on Cancer Stem Cells at Prestigious Immunotherapy Conference

January 31st, 2012 2:04 am

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd.(“ImmunoCellular” or the Company) (OTCBB: IMUC.OB - News), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012. Dr. Singh’s presentation will be titled “Targeting Cancer Stem Cells Via Immunotherapy” and will include an overview of ImmunoCellular’s clinical activities to date including ICT-107, its lead program targeting cancer stem cells (CSC) in Glioblastoma. ICT-107 is currently in a randomized phase II clinical trial at multiple centers in the US. Company is also developing two additional products targeting CSCs in tumors via modulating immune system.

Dr. Singh will also be moderating two of the panel discussions with high level executives from a number of major biotech/pharmaceutical companies. The panel discussions Dr. Singh will be moderating are “Strategic Trends in Immunotherapeutics” at 10:30 am on January 30th and “Investments and Partnership Opportunities in the Immunotherapeutics Space” at 1:30 pm on January 31st.

The Immunotherapeutics Partnering and Deal-making Conference is an immunotherapeutics business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant immunotherapeutics issues and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about immunotherapeutics business development trends, the market, and novel technologies that shape up the industry.

This conference is also part of the Novel Immunotherapeutics Summit, which consists of this track and three other tracks:

1) 4th Immunotherapeutics and Immunomonitoring

2) 10th Cytokines and Inflammation

3) Allergy Drug Discovery and Development

For more information, please visit www.gtcbio.com

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell- based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Read more:
ImmunoCellular Therapeutics To Deliver Presentation on Cancer Stem Cells at Prestigious Immunotherapy Conference

Read More...

StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision

January 31st, 2012 2:04 am

NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News) today announced the publication of preclinical data demonstrating that its proprietary HuCNS-SC(R) cells (purified human neural stem cells) protect host photoreceptors and preserve vision in an animal model of retinal disease. The preclinical results are highly relevant to human disorders of vision loss, the most notable of which is dry age-related macular degeneration (AMD). The study is available online at http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.07970.x/abstract and will be featured as the cover article in the February issue of the international peer-reviewed European Journal of Neuroscience.

This research was conducted in collaboration with a team of researchers led by Raymond Lund, Ph.D., Professor Emeritus of Ophthalmology, and Trevor McGill, Ph.D., Research Assistant Professor at the Casey Eye Institute, Oregon Health and Science University.

The results of the study show that photoreceptors, the key cells of the eye involved in vision, were protected from degeneration following transplantation of HuCNS-SC cells into the Royal College of Surgeons (RCS) rat. The RCS rat is a well-established model of retinal disease which has been used extensively to evaluate potential cell therapies. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed in the study. In humans, degeneration of the cone photoreceptors account for the unique pattern of visual loss in dry AMD.

"These results are the most robust shown to date in this animal model," said Dr. Lund, one of the study's lead investigators. "One of the more striking findings is that the effect on vision was long-lasting and correlated with the survival of HuCNS-SC cells more than seven months after transplantation, which is substantially longer than other cell types transplanted into this same model. Also important, particularly for potential clinical application, was that the cells spread from the site of initial application to cover more of the retina over time. These data suggest that HuCNS-SC cells appear to be a well-suited candidate for cell therapy in retinal degenerative conditions."

Alexandra Capela, Ph.D., another of the study's investigators and a senior scientist at StemCells, commented, "This study showed that the HuCNS-SC cells persisted and migrated throughout the retina, with no evidence of abnormal cell formation, which supports our hypothesis of a single transplant therapeutic. With this research, then, we have shown that vision can be positively impacted with a simple approach that does not require replacing photoreceptors or the RPE cells. We look forward to investigating this promising approach in the clinic later this year."

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. In addition, the Company plans to initiate a clinical trial of HuCNS-SC cells in the dry form of age-related macular degeneration in 2012, and is also pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the prospect of the Company's HuCNS-SC cells to preserve vision in animal models of retinal disease; the prospect of successful results from this research collaboration and advancing to clinical testing in age-related macular degeneration or other retinal disease; the potential of the Company's HuCNS-SC cells to treat a broad range of central nervous system disorders; the prospect and timing associated with initiating a clinical trial in a retinal disorder; and the future business operations of the Company, including its ability to conduct clinical trials as well as its other research and product development efforts. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company's HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the results of the Company's preclinical studies in retinal disease will be replicated in humans; uncertainty as to whether the FDA or other applicable regulatory agencies will permit the Company to continue clinical testing in spinal cord injury, PMD or in future clinical trials of proposed therapies for other diseases or conditions given the novel and unproven nature of the Company's technologies; uncertainties regarding the Company's ability to recruit the patients required to conduct its clinical trials or to obtain meaningful results; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company's ability to commercialize a therapeutic product and its ability to successfully compete with other products on the market; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and in its subsequent reports on Forms 10-Q and 8-K.

Go here to read the rest:
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision

Read More...

Frank Young Joins Bioheart as Financial Consultant

January 31st, 2012 2:03 am

SUNRISE, Fla., Jan. 30, 2012 (GLOBE NEWSWIRE) -- Bioheart (OTCBB:BHRT.OB - News), a leader in developing stem cell therapies to treat cardiovascular diseases, today announced that Frank Young will join Bioheart to be a financial consultant. Young will provide financial oversight of the company's capital fundraising efforts and cultivate relationships within the financial and health care communities to support Bioheart's business goals.

Young previously served as chief financial officer (CFO) with Bioheart from 2003 to 2005. He has more than 30 years' experience launching and managing venture-backed companies in the technology and health care industries.

"Frank's entrepreneurial spirit and successful fundraising strategies, combined with his previous accomplishments at Bioheart, make him an ideal fit for Bioheart," said Mike Tomas, Bioheart's president and CEO. "Frank has a proven track record launching, managing and financially advising numerous companies across the healthcare industry."

Previously Young worked as CFO with CURNA,a health care company known for its discovery of new therapeutic compounds. He engineered the sale of the company in fewer than two years for more than five times the invested capital. He also worked as CFO with Mitral Solutions and Hyperion. As CFO with Bioheart, Young assisted in raising more than $9.5 million from investors in addition to negotiating international manufacturing arrangements and joint ventures.

"I have always been impressed with Bioheart and its success with stem cell research," Young said. "I look forward to becoming an integral part of Bioheart's financial future as it continues to develop life-saving technologies for victims of heart disease."

About Bioheart

Bioheart (OTCBB:BHRT.OB - News) is committed to developing stem cell therapies to treat congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other medical problems. The company focuses on the discovery and development of therapies that will improve patients' quality of life and reduce health care costs and hospitalizations. Bioheart's leading product, MyoCell, is a muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart to improve cardiac function. For more information, visit http://www.bioheartinc.com.

For more information on Bioheart, visit http://www.bioheartinc.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

See original here:
Frank Young Joins Bioheart as Financial Consultant

Read More...

Adult Stem Cell Scientist Stem Cell Nutrition Pioneer.flv – Video

January 31st, 2012 2:03 am

10-09-2011 19:18 http://www.rhemat.stemtechbiz.com e mail chris@rhemat.co.za The Roll of Stem Cells in your Body Support the Natural Healing System of the Body

Read more from the original source:
Adult Stem Cell Scientist Stem Cell Nutrition Pioneer.flv - Video

Read More...

http://stemcellremedy.com Stem Cell Remedy User Forum

January 31st, 2012 2:03 am

05-10-2011 13:45 stemcellremedy.com Stem Cell Remedy User Forum and Blog is a global collaborative effort of regular individuals and trained researchers from organizations across the world focused on helping patients, friends and families, while avoiding the politics associated with other types of research a The sixteenth installment of my original series, "Discovering Religion". In this episode I discuss the current actions of Christian Americans to suppress modern-day scientific advancements. In particular, I address the movement by Christians to outlaw embryonic stem cell, a stance they have no justification from the Bible in taking -- a situation that very closely parallels the Church's suppression of Roger Bacon and Galileo Galilei's scientific discoveries. Additional information I could not include in the video Diabetes: Giving insulin to children with Type I Diabetes is a viable means of treating this disease, however; after 15-20 years of living with type I diabetes, the danger continues to grow, possibly leading to kidney failure, heart disease, blindness, brain damage, and premature death. This is why stem cell research is so crucial to patients suffering from this serious condition. Bone Marrow Transplants: There are many patients, both child and adult, in need of bone marrow transplants that would greatly benefit from the use of stem cells. For 2/3 of them, there is no donor with an acceptable genetic match. However, even when a match is found, it is never perfect. With stem ...

The rest is here:
http://stemcellremedy.com Stem Cell Remedy User Forum

Read More...

Page 1,492«..1020..1,4911,4921,4931,494..1,5001,510..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick